|
EP1849465A4
(en)
*
|
2005-02-18 |
2008-12-24 |
Takeda Pharmaceutical |
AGENS TO CONTROL THE FUNCTION OF THE GPR34 RECEPTOR
|
|
AU2007292816B2
(en)
*
|
2006-09-07 |
2011-11-17 |
Amgen Inc. |
Benzo-fused compounds for use in treating metabolic disorders
|
|
CA2662305C
(en)
|
2006-09-07 |
2012-04-17 |
Amgen Inc. |
Heterocyclic gpr40 modulators
|
|
EP2139843B1
(en)
*
|
2007-04-16 |
2013-12-25 |
Amgen, Inc |
Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
CN102083783A
(zh)
|
2007-10-10 |
2011-06-01 |
安姆根有限公司 |
取代的联苯gpr40调节剂
|
|
CA2703217A1
(en)
*
|
2007-10-29 |
2009-05-07 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2009111056A1
(en)
*
|
2008-03-06 |
2009-09-11 |
Amgen Inc. |
Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
|
|
EA019252B1
(ru)
|
2008-07-23 |
2014-02-28 |
Арена Фармасьютикалз, Инк. |
ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
|
|
US8586607B2
(en)
*
|
2008-07-28 |
2013-11-19 |
Syddansk Universitet |
Compounds for the treatment of metabolic diseases
|
|
SI2342205T1
(sl)
|
2008-08-27 |
2016-09-30 |
Arena Pharmaceuticals, Inc. |
Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj
|
|
AU2009303475B2
(en)
*
|
2008-10-15 |
2012-09-13 |
Amgen Inc. |
Spirocyclic GPR40 modulators
|
|
NZ592603A
(en)
*
|
2008-10-21 |
2013-02-22 |
Metabolex Inc |
Aryl gpr120 receptor agonists and uses thereof
|
|
AR074760A1
(es)
*
|
2008-12-18 |
2011-02-09 |
Metabolex Inc |
Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
|
|
WO2010085525A1
(en)
*
|
2009-01-23 |
2010-07-29 |
Schering Corporation |
Bridged and fused heterocyclic antidiabetic compounds
|
|
EP2423176A4
(en)
*
|
2009-04-22 |
2012-11-07 |
Astellas Pharma Inc |
CARBOXYLIC ACID COMPOUND
|
|
SG10201906876PA
(en)
|
2010-01-27 |
2019-09-27 |
Arena Pharm Inc |
Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
|
|
SG183416A1
(en)
|
2010-03-03 |
2012-09-27 |
Arena Pharm Inc |
Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
JP5746334B2
(ja)
*
|
2010-06-16 |
2015-07-08 |
シマベイ セラピューティクス， インコーポレーテッド |
Ｇｐｒ１２０受容体作動薬及びその使用
|
|
WO2011157827A1
(de)
|
2010-06-18 |
2011-12-22 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
WO2012120052A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8828995B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
ES2742261T3
(es)
|
2011-04-15 |
2020-02-13 |
Hivih |
Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
CN103429581B
(zh)
*
|
2012-01-12 |
2015-08-26 |
江苏恒瑞医药股份有限公司 |
多环类衍生物、其制备方法及其在医药上的应用
|
|
BR112014026651A8
(pt)
|
2012-04-26 |
2018-01-16 |
Bristol Myers Squibb Co |
derivados de imidazotiadiazol e de imidazopiridazina como inibidores do receptor ativado por proteases 4 (par4) para o tratamento de agregação plaquetária
|
|
WO2013163244A1
(en)
|
2012-04-26 |
2013-10-31 |
Bristol-Myers Squibb Company |
Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
|
|
LT2841437T
(lt)
|
2012-04-26 |
2017-09-11 |
Bristol-Myers Squibb Company |
Imidazotiadiazolo ir imidazopirazino dariniai, kaip proteazės aktyvuotų receptorių 4 (par4) inhibitoriai, skirti trombocitų agregacijos gydymui
|
|
US9527875B2
(en)
|
2012-08-02 |
2016-12-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
WO2014064215A1
(en)
|
2012-10-24 |
2014-05-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
|
|
WO2014078610A1
(en)
|
2012-11-16 |
2014-05-22 |
Bristol-Myers Squibb Company |
Dihydropyrazole gpr40 modulators
|
|
EP2953681B1
(en)
*
|
2013-02-06 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
New indanyloxydihydrobenzofuranylacetic acids
|
|
RU2015140066A
(ru)
|
2013-02-22 |
2017-03-30 |
Мерк Шарп И Доум Корп. |
Противодиабетические бициклические соединения
|
|
EP2963027B1
(en)
*
|
2013-02-28 |
2018-12-26 |
TiumBio Co., Ltd. |
Tricyclic compound and use thereof
|
|
CN104109115B
(zh)
*
|
2013-04-16 |
2016-11-23 |
中国科学院上海药物研究所 |
一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
|
|
EP2821104A1
(en)
|
2013-07-05 |
2015-01-07 |
Laboratoire Biodim |
Inhibitors of viral replication, their process of preparation and their therapeutical uses
|
|
WO2015032328A1
(zh)
*
|
2013-09-03 |
2015-03-12 |
四川海思科制药有限公司 |
茚满衍生物及其制备方法和在医药上的应用
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
ES2747973T3
(es)
*
|
2013-11-15 |
2020-03-12 |
Merck Sharp & Dohme |
Compuestos tricíclicos antidiabéticos
|
|
EP3076959B1
(en)
|
2013-12-04 |
2018-07-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
|
EP3102198B1
(en)
|
2014-02-06 |
2020-08-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic compounds
|
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
US10968193B2
(en)
|
2014-08-08 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
WO2016022446A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
|
WO2016019587A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[7, 6]-fused bicyclic antidiabetic compounds
|
|
MX386419B
(es)
|
2015-01-06 |
2025-03-18 |
Arena Pharm Inc |
Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
|
|
US10426818B2
(en)
|
2015-03-24 |
2019-10-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
|
EP3939965A1
(en)
|
2015-06-22 |
2022-01-19 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
|
|
PT3344248T
(pt)
|
2015-09-02 |
2022-06-29 |
Trevena Inc |
Compostos moduladores do recetor opioide delta contendo aza-heterocíclicos de 6 membros, composições compreendendo os mesmos e seus usos
|
|
WO2017172505A1
(en)
|
2016-03-29 |
2017-10-05 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
JP7075928B2
(ja)
*
|
2016-05-23 |
2022-05-26 |
中国医学科学院薬物研究所 |
フェニレート誘導体、調製及び医薬組成物及び使用
|
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
WO2018151834A1
(en)
|
2017-02-16 |
2018-08-23 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
|
|
MA47504A
(fr)
|
2017-02-16 |
2019-12-25 |
Arena Pharm Inc |
Composés et méthodes de traitement de l'angiocholite biliaire primitive
|
|
US11225487B2
(en)
|
2017-02-17 |
2022-01-18 |
Trevena, Inc. |
7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same
|
|
BR112019016827A2
(pt)
|
2017-02-17 |
2020-04-07 |
Trevena Inc |
compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 5 membros, métodos de uso e produção dos mesmos
|
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
CN109320483A
(zh)
*
|
2017-08-01 |
2019-02-12 |
南京大学 |
香豆素衍生物、其制备方法及其作为药物的用途
|
|
MX2020003242A
(es)
|
2017-09-22 |
2020-09-18 |
Jubilant Epipad LLC |
Compuestos heterociclicos como inhibidores de pad.
|
|
AU2018352142B2
(en)
|
2017-10-18 |
2022-08-25 |
Jubilant Epipad LLC |
Imidazo-pyridine compounds as PAD inhibitors
|
|
KR20200085836A
(ko)
|
2017-11-06 |
2020-07-15 |
주빌런트 프로델 엘엘씨 |
Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
|
|
EP3709995A4
(en)
|
2017-11-16 |
2021-04-14 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
|
BR112020010322A2
(pt)
|
2017-11-24 |
2020-11-17 |
Jubilant Episcribe Llc |
composto da fórmula i; composto da fórmula ia; composto da fórmula ib; processo de preparação de compostos da fórmula i; composição farmacêutica; método para o tratamento e/ou prevenção de várias doenças; uso dos compostos; método para o tratamento de câncer; e método para o tratamento e/ou prevenção de uma afecção mediada por prmt5 ou um distúrbio proliferativo ou câncer
|
|
TWI707849B
(zh)
|
2018-02-13 |
2020-10-21 |
美商基利科學股份有限公司 |
Pd‐1/pd‐l1抑制劑
|
|
SG11202008950PA
(en)
|
2018-03-13 |
2020-10-29 |
Jubilant Prodel LLC |
Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
|
|
KR102591947B1
(ko)
|
2018-04-19 |
2023-10-25 |
길리애드 사이언시즈, 인코포레이티드 |
Pd-1/pd-l1 억제제
|
|
ES2987794T3
(es)
|
2018-06-06 |
2024-11-18 |
Arena Pharm Inc |
Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
|
|
EP3820572B1
(en)
|
2018-07-13 |
2023-08-16 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
CN112955431A
(zh)
|
2018-09-06 |
2021-06-11 |
艾尼纳制药公司 |
可用于治疗自身免疫性病症和炎性病症的化合物
|
|
US11236085B2
(en)
|
2018-10-24 |
2022-02-01 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
EP3892616A4
(en)
*
|
2018-12-06 |
2022-07-27 |
Shanghai Jemincare Pharmaceuticals Co., Ltd. |
AROMATIC RING DERIVATIVE AS IMMUNOREGULATION AND MANUFACTURING METHOD AND APPLICATION OF AN AROMATIC RING DERIVATIVE
|
|
CN110156761B
(zh)
*
|
2019-06-18 |
2022-08-09 |
郑州大学 |
含香豆素-联苯骨架化合物、制备方法及其应用
|
|
WO2022002225A1
(zh)
*
|
2020-07-03 |
2022-01-06 |
上海美迪西生物医药股份有限公司 |
一种吲哚衍生物及其应用
|
|
CN114163426B
(zh)
|
2020-09-10 |
2024-03-19 |
上海爱博医药科技有限公司 |
苯并含氧杂环类化合物及其医药应用
|
|
CN115340484A
(zh)
*
|
2021-05-13 |
2022-11-15 |
上海美迪西生物医药股份有限公司 |
苄氧基吲哚类支链酸类衍生物及其制备方法和应用
|
|
JP2025527595A
(ja)
*
|
2022-11-22 |
2025-08-22 |
西安新通薬物研究股▲フン▼有限公司 |
新規二環系ｐｄ－ｌ１阻害剤、その製造方法、及び医薬使用
|
|
CN116283560A
(zh)
*
|
2023-02-27 |
2023-06-23 |
南通大学 |
一种基于水溶性柱芳烃的纳米诊疗材料
|
|
WO2025141118A1
(en)
*
|
2023-12-27 |
2025-07-03 |
Institut National de la Santé et de la Recherche Médicale |
Arylalkyloxyindole compounds and derivatives and their use
|